Lonza Expands Biologics Manufacturing with New GMP-Approved Filling Line in Switzerland
Key Insights
Lonza has completed a new aseptic drug product filling line in Stein, Switzerland, receiving GMP license approval from Swissmedic (search) for manufacturing highly potent biologics.
The facility features advanced containment and isolator technology that meets GMP Annex 1 requirements for sterile product manufacturing, supporting both clinical and commercial supply.
The new line strengthens Lonza's capacity for liquid and lyophilized vial filling while expanding capabilities for monoclonal antibodies (search), bi-specific antibodies, and ADCs (search).
Lonza, one of the world's largest contract development and manufacturing organizations (CDMOs), has announced the operational readiness of its new aseptic drug product filling line in Stein, Switzerland. The facility has received GMP license approval from Swissmedic (search), marking a significant expansion of the company's biologics manufacturing capabilities.
Advanced Manufacturing Technology
The new filling line incorporates the latest generation of containment and isolator technology, fulfilling GMP Annex 1 requirements for the manufacture of sterile products. This advanced containment technology enables the safe manufacturing of highly potent biologics, addressing the growing demand for specialized therapeutic modalities.
The facility strengthens Lonza's existing capacity for both liquid and lyophilized vial filling while introducing enhanced safety measures for handling potent compounds. Powered by leading manufacturing experts, the line is designed to support customers with both clinical and commercial supply requirements.
Broad Biologics Portfolio Support
The new manufacturing line can accommodate a wide range of biologics modalities, including monoclonal antibodies (search), bi-specific antibodies, and antibody-drug conjugates (ADCs (search)). This versatility positions Lonza to serve the diverse needs of biopharmaceutical companies developing next-generation therapeutics.
The expansion also enhances Lonza's growing drug product manufacturing capacity in Basel, Switzerland, creating a more robust regional manufacturing network for biologic-based therapeutics.
Integrated Manufacturing Solutions
Michael De Marco, Vice President, Head of Commercial Development, Integrated Biologics at Lonza, emphasized the strategic importance of the new facility: "The completion of our new drug product manufacturing line in Stein marks a significant milestone in our commitment to providing fully integrated end-to-end solutions for highly potent biologics such as ADCs (search). By seamlessly connecting drug substance and drug product capabilities within a single partner, Lonza enables customers to benefit from a streamlined and efficient pathway to commercialization."
This integrated approach allows Lonza to offer comprehensive services from drug substance manufacturing through final drug product filling and finishing, potentially reducing complexity and timelines for biopharmaceutical companies bringing new therapies to market.